CRA’s Andrew Tepperman provided expert testimony in multiple proceedings before the Patented Medicine Prices Review Board (PMPRB) in relation to alleged excessive pricing by pharmaceutical companies in Canada. CRA’s team addressed the application of published guidelines by the PMPRB, and the relationship between certain tests described in those guidelines and other means of evaluation whether drug prices are excessive.
Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...